


GYKI-47261 dihydrochloride

Cat. No.:	HY-19435A
CAS No.:	1217049-32-5
Molecular Formula:	C ₁₈ H ₁₇ Cl ₃ N ₄
Molecular Weight:	395.71
Target:	iGluR; Cytochrome P450
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	GYKI-47261 dihydrochloride is a competitive, orally active, and selective AMPA receptor antagonist with an IC ₅₀ of 2.5 μM. GYKI-47261 has broad spectrum anticonvulsive activity and neuroprotective effects. GYKI-47261 dihydrochloride is also a potent inducer of CYP2E1 ^{[1][2]} .								
In Vivo	<p>GYKI-47261 dihydrochloride (6 mg/kg; i.v.) shows antiischemic effect in a transient focal ischemia model, in rats. GYKI-47261 dihydrochloride (p.o.) potently mitigated the tremor induced by oxotremorine with ED₅₀ of 16.8 mg/kg in male CD1 mice^[1].</p> <p>GYKI-47261 dihydrochloride (20 mg/kg; i.p.) reverses the dopamine depleting effect of MPTP^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male C57 black mice, weighing 23-30 g^[1]</td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td>Reversed the MPTP-induced decrease in striatal concentrations.</td> </tr> </table>	Animal Model:	Male C57 black mice, weighing 23-30 g ^[1]	Dosage:	20 mg/kg	Administration:	i.p.	Result:	Reversed the MPTP-induced decrease in striatal concentrations.
Animal Model:	Male C57 black mice, weighing 23-30 g ^[1]								
Dosage:	20 mg/kg								
Administration:	i.p.								
Result:	Reversed the MPTP-induced decrease in striatal concentrations.								

REFERENCES

[1]. Abrahám G, et al. New non competitive AMPA antagonists. *Bioorg Med Chem.* 2000;8(8):2127-2143.

[2]. Tamási V, et al. GYKI-47261, a new AMPA [2-amino-3-(3-hydroxymethylisoxazole-4-yl)propionic acid] antagonist, is a CYP2E1 inducer. *Drug Metab Dispos.* 2003;31(11):1310-1314.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA